Quantitative Concept – Page 20

Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth

6 months ago talkbio0Tagged competition, Drug Industry, Eli, Eli Lilly, financial results, issues, Market, Nordisk, Obesity, Pricing, Q3 2024, Weight loss therapies

Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues

Gilead Exceeds COVID-19 Drug Sales Projections, Faces $1.75 Billion Loss on Trodelvy Trial Failure

6 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), drug sales, Failure (biologic function), Gilead, Trodelvy, Veklury

Gilead, COVID-19, Veklury, Trodelvy, drug sales, clinical trial failure

Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook

6 months ago talkbio0Tagged Advice, annual, Biktarvy, earnings, Gilead Sciences, HIV, HIV Prevention, Lenacapavir, Veklury

Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention

Medidata Introduces Bundled Solutions for Oncology and Vaccine Trials to Enhance Study Efficiency

6 months ago talkbio0Tagged adaptive trial designs, Bundled, Clinical Trials, Diversity, Efficiency, Endpoints, Medidata, Patient-Centered, Solutions, trials, Vaccines

Medidata, Oncology Trials, Vaccine Trials, Bundled Solutions, Clinical Trial Efficiency, Patient-Centered Endpoints, Adaptive Trial Designs, Trial Diversity

Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform

6 months ago talkbio0Tagged 2024, Biopharma, Donald Trump, Drug Industry, Drug Pricing Reform, Inflation, Kamala Harris, Mediation, Medicare, presidential election, Prices

Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.

Vertex Pharmaceuticals Surpasses Q3 Expectations, Boosts Annual Revenue Forecast on Strong Cystic Fibrosis Sales

6 months ago talkbio0Tagged Casgevy, Cystic Fibrosis, earnings, full-year, Genetic Therapy, revenue guidance, Suzetrigine, Trikafta sales, vanzacaftor triple, VX-548

Vertex Pharmaceuticals, Q3 2024 earnings, Cystic fibrosis treatments, Trikafta sales, Full-year revenue guidance, Genetic therapies, Vanzacaftor triple, Suzetrigine (VX-548), Casgevy